Abstract Background Children with moderate-to-severe asthma continue to have disease complications despite the receipt of standard-of-care therapy. The monoclonal antibody dupilumab has been approv...
CITATION STYLE
Bacharier, L. B., Maspero, J. F., Katelaris, C. H., Fiocchi, A. G., Gagnon, R., de Mir, I., … Hardin, M. (2021). Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. New England Journal of Medicine, 385(24), 2230–2240. https://doi.org/10.1056/nejmoa2106567
Mendeley helps you to discover research relevant for your work.